Salarius Pharmaceuticals, Inc. filed its 10-K on Mar 27, 2023 for the period ending Dec 31, 2022. In this report its auditor, Ernst & Young LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.5 USD | -1.46% | -0.20% | -23.08% |
25/03 | Wall Street Set to Open Modestly Lower Monday Ahead of Housing, Inflation Data | MT |
25/03 | Top Premarket Gainers | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-23.08% | 2.16M | |
+17.96% | 44.96B | |
+1.17% | 42.65B | |
+48.77% | 41.85B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |
- Stock Market
- Equities
- SLRX Stock
- News Salarius Pharmaceuticals, Inc.
- Salarius Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt